ArticleJAAD international2026
Global patterns of melanoma, burden attributable to ultraviolet radiation exposure, and projections to 2050 across 185 countries: A population-based study with global modeling.
Article in JAAD international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Burdens of Malignant Melanoma and Projections for 2050 in Asia: Findings from the 2023 Global Burden of Disease Study.Clinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ultraviolet radiation (UVR) is a well-established modifiable risk factor for malignant melanoma, yet global estimates of its attributable burden remain limited. Objectives: To provide up-to-date global estimates of the melanoma burden and quantify the contribution of UVR. Methods: We examined melanoma burden in 2022, the most recent ten-year trends, and projected estimates for 2050 by sex, age, and Human Development Index (HDI) using GLOBOCAN data, CI5plus, and the World Health Organization Mortality Databases. As a secondary analysis, population attributable fractions for UVR exposure were calculated for 2022 and 2050, using sex-specific reference populations with low exposure, incorporating demographic changes in the projections. Results: In 2022, an estimated 330,000 new melanoma cases were reported, with ∼88% attributable to UVR using the fifth percentile reference. Incidence, overall and UVR-attributable, was highest in high-HDI countries, especially Oceania and Northern Europe, while mortality-to-incidence ratios were highest in low-HDI settings. By 2050, UVR-attributable cases are projected to rise, with the steepest growth in low- and medium-HDI settings. Limitations: Models are subject to uncertainties in cancer registration, especially in low-HDI regions. Conclusion: Melanoma remains largely UVR-attributable, with substantial regional disparities. The projected increase in UVR-attributable melanoma burden in lower-HDI settings underscores the urgent need for region-specific prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.